Lantheus Announces Presentation of Data at the 2026 Clinical Trials on Alzheimer’s Disease Annual Meeting
Lantheus Holdings (NASDAQ: LNTH) announced two poster presentations at the Clinical Trials on Alzheimer’s Disease Annual Meeting on November 16–19, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Lantheus Holdings (NASDAQ: LNTH) announced two poster presentations at the Clinical Trials on Alzheimer’s Disease Annual Meeting on November 16–19, 2026. The meeting will take place in Boston.
Poster P077 addresses the diagnostic performance of florquinitau F 18 PET imaging for detecting tau pathology in early Alzheimer’s disease in pivotal phase 3 studies. Poster P082 concerns age dependence of astrocytic MAO-B using 18F-FDED PET imaging across the Alzheimer’s disease spectrum. Both posters are scheduled in the MRI & Imaging session, from November 16 at 2:00 p.m. ET through November 17 at 5:30 p.m. ET. Christopher Rowe of Austin Health will present P077, and Gerard Nisal Bischof of Lantheus will present P082.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BEDFORD, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announced data to be featured at the 2026 Clinical Trials on Alzheimer’s Disease (CTAD) Annual Meeting, taking place November 16 – November 19, 2026 in Boston, MA.
Presentation details are as follows:
Date & Time: Monday, November 16 (2:00 p.m. ET) – Tuesday, November 17 (5:30 p.m. ET)
Session Type: Poster
Session Title: MRI & Imaging
Poster Number: P077
Title: Detection of tau pathology in patients with early Alzheimer’s disease: Diagnostic performance of florquinitau F 18 PET in pivotal phase 3 studies
Presenter: Christopher Rowe, MD BMBS, FRACP, FAANMS, Director of Molecular Imaging Research at Austin Health
Poster Number: P082
Title: Minimal age dependence of astrocytic MAO-B with 18F-FDED PET Imaging in the Alzheimer’s disease spectrum
Presenter: Gerard Nisal Bischof, PD, Director Medical Imaging at Lantheus
About Lantheus
Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in New Jersey, Canada, Germany, Sweden, Switzerland and the United Kingdom, Lantheus has been providing radiopharmaceutical solutions for 70 years. For more information, visit www.lantheus.com.
Contacts:
Lantheus
Mark Kinarney
Vice President, Investor Relations
978-671-8842
ir@lantheus.com
Melissa Downs
Executive Director, External Communications
646-975-2533
media@lantheus.com
